Achievements as Country Supervisor-Ghana at Actavis(now Allergan) (2014 - present)
1. Successful Launch of Cyclogest® in the country although the problems on the ground.
2. Penetrating the most important centers including governmental, military hospitals and private centers as well.
3. Building up many loyal physicians to the company that sounded well in the whole country.
4. Arranging many CMEs programs to support the junior physicians and nurses.

Achievements as Country Supervisor-Libya at Actavis(now Allergan) (2014 - 2014)
1. Leading the Company market growth of 20% in the first semester of 2014(in Market sales)
2. Restructuring the team and the targets to include the public sector that significantly developed the public sales for the first semester and the whole year later on.
3. Launching the Oncology portfolio for the first time in the country.

Achievements as Team Leader at MSD (2013 - 2014)
2013,
1. Developing the In Market sales of Peg intron for TMC from 500 vials in 2012 to 2050 vials in 2013 as TMC was assigned to my territory starting Feb 20th.
2. Releasing three important recommendations for Boceprevir of about 90 patients from TCH and TMC that will enhance the introduction of the product in 2014.

Achievements as Product Specialist at MSD (2010 - 2012)
1. Introducing Peg intron for the first time to Sabha territory (Southern Region) after a lot of difficulties and follow up.
2. First introduction of Peg intron to Gastroenterology department at Tripoli central hospital which considered a new channel for the product sales growth.
3. Achieving 100% of sales target although a lot of instabilities and confusions in Libya after the revolution.
4. 4-Increasing the market share of Peg intron in Libya from 25% to almost 60% and this was proven from the enrolling patients follow up and from the tender listed amounts (Due to absence of IMS Data).
5. Organizing, managing and presenting medical, marketing and skills training sessions for the market access team which positively impacted 2012 team performance.
. Number of Remicade enrolled cases at Dermatology Department -Tripoli Central Hospital, reached twelve cases for the first time.
. Releasing a recommendation for Emend &Noxafil; (new products) that could be of help in listing both in tender.

Achievements as product Specialist at Bayer (2009 - 2010)
1. Adalat 30 LA, Glucobay &Avalox; were introduced to Ibn Sina Hospital, Benghazi, Libya for The first time.
2. Benghazi Adalat 30 &60; were introduced to hospital El Gomhoria Benghazi for the first time &Avalox; 400mg IV consumption was doubled through the second semester of the year 2009 at the same hospital.
3. Best Achiever reward from AL-Amal CO for the year 2009 for the remarkable growth in Bayer products in Benghazi.

Achievements as Medical Rep at Servier (2005 - 2009)
1- Year (2008-2009) best achiever &over; target, delta territory, in all products for the first quarter.
2- Year (2006), Coversyl 4 mg & Vastarel MR were introduced to Hospital Desok El am which is a governmental general hospital.
3- Year (2006), Vastarel MR (for the first time) was introduced to Hospital El Obour Kafr El Sheikh which is a medical insurance governmental hospital.
4- Year(2006-2007), Vastarel MR 108% growth, 22% over budget &Diamicron; 60mg 96% growth, 16%over budget.
5- Year (2005-2006), Coversyl 4 mg 67% growth which was greater than the total company (40%).

Other achievements in school, university, sports, etc...